Psychopharmacology

Latest News

The company has announced plans to submit the NDA in the first half of 2025.
FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD

May 21st 2024

“The findings emphasize the importance of monitoring the use of psychotropic combinations, particularly among vulnerable populations.”
Psychotropic Polypharmacy Trends Rise Among Child, Adolescent Medicaid Beneficiaries

May 21st 2024

Here are highlights from the week in Psychiatric Times.
The Week in Review: May 13-17

May 18th 2024

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.
Examining a Case of Psychiatric Polypharmacy-Related Agranulocytosis

May 17th 2024

Latest CME Events & Activities

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Real Psychiatry 2025

January 2025 - Exact Date TBA

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

More News

© 2024 MJH Life Sciences

All rights reserved.